Skip to main content
. 2023 Apr 20;61(4):2201514. doi: 10.1183/13993003.01514-2022

TABLE 4.

Secondary end-points

Intention-to-treat analysis Per-protocol analysis
MP (n=337) DM (n=340) p-value# MP (n=279) DM (n=286) p-value#
Mechanical ventilation-free days at 28 days 23.0 (14.0) 24.0 (16.0) 0.49 24.0 (10.0) 26.0 (8.0) 0.09
 Invasive mechanical ventilation-free days at 28 days 28.0 (0.0) 28.0 (0.0) 0.92 28.0 (0.0) 28.0 (0.0) 0.93
Days of hospitalisation among survivors 15.0 (11.0) 14.0 (11.0) 0.005 15 (10.0) 13 (10.0) 0.001
Tracheostomy, n (%) 8.0 (2.4) 9.0 (2.6) 0.82 3.0 (1.1) 6.0 (2.1) 0.33
CRP (mg·L−1)
 Day 3 32.0 (57.5) 37.7 (56.6) 0.16
 Day 7 8.6 (21.9) 12.4 (28.9) 0.006
 Day 14 5.0 (21.8) 11.5 (36.2) 0.0001
PaO2/FIO2 (mmHg)
 Day 3 187.0 (132.0) 192.0 (138.0) 0.40
 Day 7 213.0 (146.0) 227.4 (151.0) 0.20
 Day 14 253.2 (159.0) 264.4 (165.5) 0.67
ICU referral, n (%) 41.0 (12.2) 45.0 (13.2) 0.68 7.0 (2.1) 19.0 (5.6) 0.02

Data are presented as median (interquartile range), unless otherwise stated. MP: methylprednisolone; DM: dexamethasone; CRP: C-reactive protein; PaO2/FIO2: ratio of arterial oxygen tension (mmHg) to inspiratory oxygen fraction; ICU: intensive care unit. #: p-value of the Mann–Whitney test for numerical variables, or the Chi-squared test or Fisher's exact test for dichotomous variable, as appropriate.